v3.26.1
Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
General and administrative:        
Stock-based compensation $ 12,093 $ 1,273 $ 13,379 $ 2,659
Acquired in-process research and development 59,000 0 59,000 0
Intangible asset impairment charge 0 0 67,808 0
Fair value adjustment for contingent consideration 0 532 (64,330) 2,456
Total operating expenses 79,782 10,427 94,372 25,285
Loss from operations (79,782) (10,427) (94,372) (25,285)
Fair value adjustment for warrants 4,507 (4,464) 35,623 (4,464)
Warrant issuance costs (874) (872) (874) (872)
Net income (loss) (75,488) (16,049) (39,576) (31,079)
Reportable Segment        
Research and development:        
Personnel 2,105 1,294 4,019 2,614
Stock-based compensation 3,182 438 3,724 873
Clinical and contract manufacturing 1,173 5,342 4,773 12,069
Other (999) (521) (210) (858)
General and administrative:        
Personnel 2,102 1,038 3,438 2,765
Stock-based compensation 8,911 834 9,655 1,785
Consulting and professional costs 4,981 786 6,539 2,252
Other 632 684 1,261 1,329
Acquired in-process research and development 59,000 0 59,000 0
Gain on Orphai Acquisition (1,305) 0 (1,305) 0
Intangible asset impairment charge 0 0 67,808 0
Fair value adjustment for contingent consideration 0 532 (64,330) 2,456
Total operating expenses 79,782 10,427 94,372 25,285
Loss from operations (79,782) (10,427) (94,372) (25,285)
Fair value adjustment for debt 0 (501) 12,168 (945)
Fair value adjustment for warrants 4,507 (4,464) 35,623 (4,464)
Warrant issuance costs (874) (872) (874) (872)
Other segment items 661 215 7,879 487
Net income (loss) $ (75,488) $ (16,049) $ (39,576) $ (31,079)